AGTC to Present at the 29th Annual ROTH Conference on March 14, 2017
March 03 2017 - 7:00AM
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a
biotechnology company conducting human clinical trials of
adeno-associated virus (AAV)-based gene therapies for the treatment
of rare diseases, today announced that Sue Washer, President and
Chief Executive Officer, will present at the 29th Annual ROTH
Conference on Tuesday, March 14, 2017 at 8:30am PT (11:30am ET) in
Dana Point, Calif.
AGTC's lead product candidates are designed to treat inherited
orphan diseases of the eye, caused by mutations in single genes
that significantly affect visual function and currently lack
effective medical treatments.
AGTC's pipeline includes ophthalmology programs in X-linked
retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP),
achromatopsia caused by mutations in the CNGB3 and CNGA3 genes, wet
age-related macular degeneration and our optogenetics program with
Bionic Sight.
A live audio webcast of the presentation can be accessible by
visiting ir.agtc.com/events.cfm. A replay will be available on the
company’s website following the event.
About AGTC
AGTC is a clinical-stage biotechnology company that uses its
proprietary gene therapy platform to develop treatments designed to
transform the lives of patients with severe diseases, with an
initial focus in ophthalmology. AGTC's product pipeline includes
ophthalmology programs in X-linked retinoschisis (XLRS), X-linked
retinitis pigmentosa (XLRP), both partnered with Biogen,
achromatopsia caused by mutations in the CNGB3 and CNGA3 genes, wet
age-related macular degeneration, and our collaborative
optogenetics program with Bionic Sight. AGTC’s non-ophthalmology
programs include its adrenoleukodystrophy program, also partnered
with Biogen, and its otology research program. The otology programs
are in pre-clinical development and the company expects to advance
several otology product candidates into clinical development in the
next few years. AGTC employs a highly-targeted approach to
selecting and designing its product candidates, choosing to develop
therapies for indications having high unmet medical need that it
believes are clinically feasible and present commercial
opportunities. AGTC has a significant intellectual property
portfolio and extensive expertise in the design of gene therapy
products including capsids, promoters and expression cassettes, as
well as, expertise in the formulation, manufacture and physical
delivery of gene therapy treatments
IR/PR CONTACTS:
David Carey (IR) or Danielle Lewis (PR)
Lazar Partners Ltd.
T: (212) 867-1768 or (212) 843-0211
dcarey@lazarpartners.com or dlewis@lazarpartners.com
CORPORATE CONTACTS:
Larry Bullock
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (386) 462-2204
lbullock@agtc.com
Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Sep 2023 to Sep 2024